KYNTRA BIO, INC.: retained earnings or deficit
Retained earnings or deficit for KYNTRA BIO, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All KYNTRA BIO, INC. financial histories
What this measure means
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
Exact concept: us-gaap:RetainedEarningsAccumulatedDeficit. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2014-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | -1,706,047,000 | USD | 2026-03-16 | 10-K · 0001193125-26-108346 |
| At date | 2024-12-31 | -1,889,499,000 | USD | 2026-03-16 | 10-K · 0001193125-26-108346 |
| At date | 2023-12-31 | -1,841,920,000 | USD | 2025-03-17 | 10-K · 0000950170-25-040280 |
| At date | 2022-12-31 | -1,557,688,000 | USD | 2024-02-26 | 10-K · 0000950170-24-020161 |
| At date | 2021-12-31 | -1,264,034,000 | USD | 2023-02-27 | 10-K · 0000950170-23-004668 |
| At date | 2020-12-31 | -974,011,000 | USD | 2022-03-04 | 10-K/A · 0001564590-22-008804 |
| At date | 2019-12-31 | -784,720,000 | USD | 2021-03-01 | 10-K · 0001564590-21-009871 |
| At date | 2018-12-31 | -715,827,000 | USD | 2020-03-02 | 10-K · 0001564590-20-008161 |
| At date | 2017-12-31 | -630,657,000 | USD | 2020-03-02 | 10-K · 0001564590-20-008161 |
| At date | 2016-12-31 | -509,782,000 | USD | 2019-02-27 | 10-K · 0001564590-19-004979 |
| At date | 2015-12-31 | -451,714,000 | USD | 2019-02-27 | 10-K · 0001564590-19-004979 |
| At date | 2014-12-31 | -322,283,000 | USD | 2016-02-29 | 10-K · 0001564590-16-013728 |
Related financial histories
- KYNTRA BIO, INC.: total assets
- KYNTRA BIO, INC.: total liabilities
- KYNTRA BIO, INC.: stockholders equity
- KYNTRA BIO, INC.: cash and cash equivalents
- KYNTRA BIO, INC.: net income or loss
- KYNTRA BIO, INC.: operating cash flow
- KYNTRA BIO, INC.: capital expenditure payments
- KYNTRA BIO, INC.: revenue
- KYNTRA BIO, INC.: contract revenue excluding tax
- KYNTRA BIO, INC.: financing cash flow
- KYNTRA BIO, INC.: investing cash flow
- KYNTRA BIO, INC.: basic weighted-average shares
- KYNTRA BIO, INC.: diluted weighted-average shares
- KYNTRA BIO, INC.: basic earnings per share
- KYNTRA BIO, INC.: diluted earnings per share
- KYNTRA BIO, INC.: income tax expense or benefit
- KYNTRA BIO, INC.: net property, plant and equipment
- KYNTRA BIO, INC.: share-based compensation expense
- KYNTRA BIO, INC.: operating income or loss
- KYNTRA BIO, INC.: current assets
- KYNTRA BIO, INC.: interest expense
- KYNTRA BIO, INC.: current liabilities
- KYNTRA BIO, INC.: current accounts payable
- KYNTRA BIO, INC.: net current accounts receivable
- KYNTRA BIO, INC.: operating expenses
- KYNTRA BIO, INC.: net inventory
- KYNTRA BIO, INC.: cost of revenue
- KYNTRA BIO, INC.: selling, general and administrative expense
- KYNTRA BIO, INC.: research and development expense
Inspect the source
- Entity
- KYNTRA BIO, INC. / CIK 0000921299
- Captured
- 2026-09-20T05:08:01.696Z
- SEC response SHA-256
60313741a614d381e73fc033725566bd06ee27593e71b4e95a10100fd7a817db
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000921299.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))